The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Substantia Nigra

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Substantia Nigra


Psychiatry related information on Substantia Nigra


High impact information on Substantia Nigra


Chemical compound and disease context of Substantia Nigra


Biological context of Substantia Nigra


Anatomical context of Substantia Nigra


Associations of Substantia Nigra with chemical compounds


Gene context of Substantia Nigra


Analytical, diagnostic and therapeutic context of Substantia Nigra


  1. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Hirsch, E., Graybiel, A.M., Agid, Y.A. Nature (1988) [Pubmed]
  2. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Liberatore, G.T., Jackson-Lewis, V., Vukosavic, S., Mandir, A.S., Vila, M., McAuliffe, W.G., Dawson, V.L., Dawson, T.M., Przedborski, S. Nat. Med. (1999) [Pubmed]
  3. Glucose, sulfonylureas, and neurotransmitter release: role of ATP-sensitive K+ channels. Amoroso, S., Schmid-Antomarchi, H., Fosset, M., Lazdunski, M. Science (1990) [Pubmed]
  4. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Burns, R.S., Chiueh, C.C., Markey, S.P., Ebert, M.H., Jacobowitz, D.M., Kopin, I.J. Proc. Natl. Acad. Sci. U.S.A. (1983) [Pubmed]
  5. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Frim, D.M., Uhler, T.A., Galpern, W.R., Beal, M.F., Breakefield, X.O., Isacson, O. Proc. Natl. Acad. Sci. U.S.A. (1994) [Pubmed]
  6. Huntington's disease: changes in tachykinin content in postmortem brains. Arai, H., Emson, P.C., Carrasco, L.H. Ann. Neurol. (1987) [Pubmed]
  7. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Schlossmacher, M.G., Frosch, M.P., Gai, W.P., Medina, M., Sharma, N., Forno, L., Ochiishi, T., Shimura, H., Sharon, R., Hattori, N., Langston, J.W., Mizuno, Y., Hyman, B.T., Selkoe, D.J., Kosik, K.S. Am. J. Pathol. (2002) [Pubmed]
  8. Subsensitivity of catecholaminergic neurons to direct acting agonists after single or repeated electroconvulsive shock. Tepper, J.M., Nakamura, S., Spanis, C.W., Squire, L.R., Young, S.J., Groves, P.M. Biol. Psychiatry (1982) [Pubmed]
  9. Bipolar disorders, dystonia, and compulsion after dysfunction of the cerebellum, dentatorubrothalamic tract, and substantia nigra. Lauterbach, E.C. Biol. Psychiatry (1996) [Pubmed]
  10. Relationship of changes in spontaneous motor activity to spontaneous circling in rats with unilateral 6-hydroxydopamine lesions of the substantia nigra. Carey, R.J. Exp. Neurol. (1986) [Pubmed]
  11. Mosaicism for a specific somatic mitochondrial DNA mutation in adult human brain. Soong, N.W., Hinton, D.R., Cortopassi, G., Arnheim, N. Nat. Genet. (1992) [Pubmed]
  12. Angiotensin-converting enzyme in substantia nigra of schizophrenics. Owen, F., Lofthouse, R., Crow, T.J. N. Engl. J. Med. (1980) [Pubmed]
  13. Dopamine covalently modifies and functionally inactivates parkin. LaVoie, M.J., Ostaszewski, B.L., Weihofen, A., Schlossmacher, M.G., Selkoe, D.J. Nat. Med. (2005) [Pubmed]
  14. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Xu, J., Kao, S.Y., Lee, F.J., Song, W., Jin, L.W., Yankner, B.A. Nat. Med. (2002) [Pubmed]
  15. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Klivenyi, P., Ferrante, R.J., Matthews, R.T., Bogdanov, M.B., Klein, A.M., Andreassen, O.A., Mueller, G., Wermer, M., Kaddurah-Daouk, R., Beal, M.F. Nat. Med. (1999) [Pubmed]
  16. Herpes simplex virus vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine-induced degeneration of neurons in the substantia nigra in vivo. Yamada, M., Oligino, T., Mata, M., Goss, J.R., Glorioso, J.C., Fink, D.J. Proc. Natl. Acad. Sci. U.S.A. (1999) [Pubmed]
  17. Sexual dimorphism and developmental regulation of substantia nigra function. Velísková, J., Moshé, S.L. Ann. Neurol. (2001) [Pubmed]
  18. Oxygen deprivation activates an ATP-inhibitable K+ channel in substantia nigra neurons. Jiang, C., Sigworth, F.J., Haddad, G.G. J. Neurosci. (1994) [Pubmed]
  19. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Piggott, M.A., Marshall, E.F., Thomas, N., Lloyd, S., Court, J.A., Jaros, E., Burn, D., Johnson, M., Perry, R.H., McKeith, I.G., Ballard, C., Perry, E.K. Brain (1999) [Pubmed]
  20. Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease. Fernandez, A., de Ceballos, M.L., Rose, S., Jenner, P., Marsden, C.D. Brain (1996) [Pubmed]
  21. Differential localization of type I and type II benzodiazepine binding sites in substantia nigra. Lo, M.M., Niehoff, D.L., Kuhar, M.J., Snyder, S.H. Nature (1983) [Pubmed]
  22. Overlapping and distinct actions of the neurotrophins BDNF, NT-3, and NT-4/5 on cultured dopaminergic and GABAergic neurons of the ventral mesencephalon. Hyman, C., Juhasz, M., Jackson, C., Wright, P., Ip, N.Y., Lindsay, R.M. J. Neurosci. (1994) [Pubmed]
  23. Bilateral alterations in local cerebral glucose utilization following intranigral application of the GABAergic agonist muscimol. Dermon, C.R., Pizarro, P., Georgopoulos, P., Savaki, H.E. J. Neurosci. (1990) [Pubmed]
  24. Glial cell line-derived neurotrophic factor/neurturin-induced differentiation and its enhancement by retinoic acid in primary human neuroblastomas expressing c-Ret, GFR alpha-1, and GFR alpha-2. Hishiki, T., Nimura, Y., Isogai, E., Kondo, K., Ichimiya, S., Nakamura, Y., Ozaki, T., Sakiyama, S., Hirose, M., Seki, N., Takahashi, H., Ohnuma, N., Tanabe, M., Nakagawara, A. Cancer Res. (1998) [Pubmed]
  25. Extrasynaptic vesicular transmitter release from the somata of substantia nigra neurons in rat midbrain slices. Jaffe, E.H., Marty, A., Schulte, A., Chow, R.H. J. Neurosci. (1998) [Pubmed]
  26. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Markey, S.P., Johannessen, J.N., Chiueh, C.C., Burns, R.S., Herkenham, M.A. Nature (1984) [Pubmed]
  27. In vivo release of acetylcholinesterase in cat substantia nigra and caudate nucleus. Greenfield, S., Cheramy, A., Leviel, V., Glowinski, J. Nature (1980) [Pubmed]
  28. Dendritic release of dopamine in the substantia nigra. Cheramy, A., Leviel, V., Glowinski, J. Nature (1981) [Pubmed]
  29. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Tomac, A., Lindqvist, E., Lin, L.F., Ogren, S.O., Young, D., Hoffer, B.J., Olson, L. Nature (1995) [Pubmed]
  30. Epidermal growth factor immunoreactive material in the central nervous system: location and development. Fallon, J.H., Seroogy, K.B., Loughlin, S.E., Morrison, R.S., Bradshaw, R.A., Knaver, D.J., Cunningham, D.D. Science (1984) [Pubmed]
  31. The role of GABA in the substantia nigra. James, T.A., Starr, M.S. Nature (1978) [Pubmed]
  32. Functional receptor for GDNF encoded by the c-ret proto-oncogene. Trupp, M., Arenas, E., Fainzilber, M., Nilsson, A.S., Sieber, B.A., Grigoriou, M., Kilkenny, C., Salazar-Grueso, E., Pachnis, V., Arumäe, U. Nature (1996) [Pubmed]
  33. Facilitation of a dendritic calcium conductance by 5-hydroxytryptamine in the substantia nigra. Nedergaard, S., Bolam, J.P., Greenfield, S.A. Nature (1988) [Pubmed]
  34. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Hantraye, P., Brouillet, E., Ferrante, R., Palfi, S., Dolan, R., Matthews, R.T., Beal, M.F. Nat. Med. (1996) [Pubmed]
  35. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Turski, L., Bressler, K., Rettig, K.J., Löschmann, P.A., Wachtel, H. Nature (1991) [Pubmed]
  36. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Hyman, C., Hofer, M., Barde, Y.A., Juhasz, M., Yancopoulos, G.D., Squinto, S.P., Lindsay, R.M. Nature (1991) [Pubmed]
  37. Pitx3 is required for development of substantia nigra dopaminergic neurons. Nunes, I., Tovmasian, L.T., Silva, R.M., Burke, R.E., Goff, S.P. Proc. Natl. Acad. Sci. U.S.A. (2003) [Pubmed]
  38. Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease. van der Walt, J.M., Noureddine, M.A., Kittappa, R., Hauser, M.A., Scott, W.K., McKay, R., Zhang, F., Stajich, J.M., Fujiwara, K., Scott, B.L., Pericak-Vance, M.A., Vance, J.M., Martin, E.R. Am. J. Hum. Genet. (2004) [Pubmed]
  39. Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo. Hagg, T., Varon, S. Proc. Natl. Acad. Sci. U.S.A. (1993) [Pubmed]
  40. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Beck, K.D., Valverde, J., Alexi, T., Poulsen, K., Moffat, B., Vandlen, R.A., Rosenthal, A., Hefti, F. Nature (1995) [Pubmed]
  41. Dopamine modulation of the effects of gamma-aminobutyric acid on substantia nigra pars reticulata neurons. Waszcak, B.L., Walters, J.R. Science (1983) [Pubmed]
  42. Normalization of spiroperidol binding in the denervated rat striatum by homologous grafts of substantia nigra. Freed, W.J., Ko, G.N., Niehoff, D.L., Kuhar, M.J., Hoffer, B.J., Olson, L., Cannon-Spoor, H.E., Morihisa, J.M., Wyatt, R.J. Science (1983) [Pubmed]
  43. Glucose modulates rat substantia nigra GABA release in vivo via ATP-sensitive potassium channels. During, M.J., Leone, P., Davis, K.E., Kerr, D., Sherwin, R.S. J. Clin. Invest. (1995) [Pubmed]
  44. Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies. Levey, A.I., Hersch, S.M., Rye, D.B., Sunahara, R.K., Niznik, H.B., Kitt, C.A., Price, D.L., Maggio, R., Brann, M.R., Ciliax, B.J. Proc. Natl. Acad. Sci. U.S.A. (1993) [Pubmed]
WikiGenes - Universities